AbstractObjectivesThe aim of this study was to evaluate percutaneous coronary intervention (PCI) in the Assessment of the Safety and Efficacy of New Thrombolytic Regimens (ASSENT-3) trial.BackgroundIn the ASSENT-3 trial, co-therapy with abciximab (ABC) or enoxaparin (ENOX) reduced ischemic complications after ST-elevation acute myocardial infarction treated with tenecteplase when compared with unfractionated heparin (UFH). The effect of these new co-therapies on the results of PCI is unknown.MethodsClinical outcomes in patients who received co-therapy with ABC, ENOX, or UFH and subsequently underwent an elective (n = 1,064) or urgent (n = 716) PCI in the ASSENT-3 trial were compared.ResultsNo significant differences in clinical end points w...
AbstractObjectivesThe aims of the Safety and Efficacy of Subcutaneous Enoxaparin Versus Intravenous ...
AbstractOBJECTIVESWe performed a multicenter, double-blind placebo-controlled trial to examine the e...
ObjectivesThis study was designed to determine the impact of bivalirudin on 1-year outcomes in acute...
AbstractObjectivesThe aim of this study was to evaluate percutaneous coronary intervention (PCI) in ...
OBJECTIVES: The aim of this study was to evaluate percutaneous coronary intervention (PCI) in the As...
ObjectivesThis study reports a prospectively planned analysis of patients with acute coronary syndro...
BackgroundFondaparinux compared to enoxaparin has been showed to reduce the bleeding risk in acute c...
AbstractObjectivesThis study was designed to assess whether use of enoxaparin during percutaneous co...
ObjectivesWe sought to evaluate whether enoxaparin (ENOX) is superior to unfractionated heparin (UFH...
ObjectivesThe purpose of this study was to determine the efficacy and safety of enoxaparin (ENOX) ve...
ObjectivesThe aim of this study was to assess the risk-benefit of enoxaparin (Sanofi-Aventis, Paris,...
ObjectivesThe purpose of this study was to compare the effect of receiving pretreatment with antithr...
Background: the combined use of anticoagulants, antiplatelet agents, and invasive coronary procedure...
ObjectivesThe goal of this study was to evaluate glycoprotein IIb/IIIa inhibition with eptifibatide ...
Backround: The optimal antithrombotic treatment during a primary percutaneous coronary intervention ...
AbstractObjectivesThe aims of the Safety and Efficacy of Subcutaneous Enoxaparin Versus Intravenous ...
AbstractOBJECTIVESWe performed a multicenter, double-blind placebo-controlled trial to examine the e...
ObjectivesThis study was designed to determine the impact of bivalirudin on 1-year outcomes in acute...
AbstractObjectivesThe aim of this study was to evaluate percutaneous coronary intervention (PCI) in ...
OBJECTIVES: The aim of this study was to evaluate percutaneous coronary intervention (PCI) in the As...
ObjectivesThis study reports a prospectively planned analysis of patients with acute coronary syndro...
BackgroundFondaparinux compared to enoxaparin has been showed to reduce the bleeding risk in acute c...
AbstractObjectivesThis study was designed to assess whether use of enoxaparin during percutaneous co...
ObjectivesWe sought to evaluate whether enoxaparin (ENOX) is superior to unfractionated heparin (UFH...
ObjectivesThe purpose of this study was to determine the efficacy and safety of enoxaparin (ENOX) ve...
ObjectivesThe aim of this study was to assess the risk-benefit of enoxaparin (Sanofi-Aventis, Paris,...
ObjectivesThe purpose of this study was to compare the effect of receiving pretreatment with antithr...
Background: the combined use of anticoagulants, antiplatelet agents, and invasive coronary procedure...
ObjectivesThe goal of this study was to evaluate glycoprotein IIb/IIIa inhibition with eptifibatide ...
Backround: The optimal antithrombotic treatment during a primary percutaneous coronary intervention ...
AbstractObjectivesThe aims of the Safety and Efficacy of Subcutaneous Enoxaparin Versus Intravenous ...
AbstractOBJECTIVESWe performed a multicenter, double-blind placebo-controlled trial to examine the e...
ObjectivesThis study was designed to determine the impact of bivalirudin on 1-year outcomes in acute...